Outcome of Breast Cancer in Moroccan Young Women Correlated to Clinic-Pathological Features, Risk Factors and Treatment: A Comparative Study of 716 Cases in a Single Institution

Meriem Slaoui1,2*, Fatima Zahra Mouh1,2, Imane Ghanname3, Rachid Razine4,5, Mohammed El Mzibri2, Mariam Amrani1

1 Equipe de recherche ONCOGYM A, University of Mohamed V Rabat, Faculty of Medicine and Pharmacy of Rabat, Avenue Mohammed Belarbi El Alaoui–Souissi–BP 6203 Rabat, Morocco, 2 Unité de Biologie et Recherche Médicale, Centre National de l’Energie, des Sciences et des Techniques Nucléaires, Rabat, Morocco, 3 Faculty of Medicine and Pharmacy, University Mohammed V Rabat, Avenue Mohammed Belarbi El Alaoui–Souissi–BP 6203 Rabat, Morocco, 4 Laboratory of Biostatistics, Epidemiology and Clinical Research, University of Mohamed V Rabat, Faculty of Medicine and Pharmacy of Rabat, Avenue Mohammed Belarbi El Alaoui–Souissi–BP 6203 Rabat, Morocco, 5 Department of Public Health, University of Mohamed V Rabat, Faculty of Medicine and Pharmacy of Rabat, Avenue Mohammed Belarbi El Alaoui–Souissi–BP 6203 Rabat, Morocco

* meriem.slaoui@um5s.net.ma

Abstract

Background
Breast cancer in young women is quite uncommon and shows more aggressive characteristics with major disparities between worldwide populations. Prognosis and outcome of breast cancer in young patients are widely studied, but still no consensus is available.

Methods
We retrospectively included 716 cases of breast cancer women diagnosed in 2009 at the National Institute of Oncology of Rabat. Patients were divided into two groups according to their age: women aged ≤40 years (Group 1) and women aged >40 years (Group 2). Data were recorded from patients’ medical files and analyzed using SPSS 13.0 software (IBM).

Results
Young patients represent 24.9% of all patients with breast cancer. The comparison between the two groups displayed significant differences regarding nulliparity (p = 0.001) and progesterone receptor negativity (p = 0.01). Moreover, more progression (Metastases/Relapse) was registered in young women as compared to older women with breast cancer (p = 0.03).
The estimated median follow-up period was 31 months. The 5-years Event-Free Survival (EFS) of patients with local disease was 64.6% in young women and 71.5% in older women with breast cancer \( (p = 0.04) \). Multivariate analysis in young women showed that nulliparity (HR: 7.2; 95%CI: 1.16–44.54; \( p = 0.03 \)), T3 tumors (HR: 17.39; 95%CI: 1.74–173.34; \( p = 0.01 \)) and negative PgR status (HR: 19.85; 95%CI: 1.07–366.54; \( p = 0.04 \)) can be considered as risk factors for poorer event free survival while hormone therapy was associated with better EFS (HR: 0.11; 95%CI: 0.00–0.75; \( p = 0.03 \)). In Group 2, multivariate analysis showed that patients with inflammatory breast cancer, N+ status, absence of radiotherapy, absence of chemotherapy, and absence of hormone therapy are at increased risk of recurrence.

**Conclusions**

In Morocco, breast cancer is more frequent in young women as compared to western countries. Breast cancer in young women is more aggressive and is diagnosed late, leading to an intensive treatment. Moreover, the main factors associated with breast cancer development in young women would be hormonal and reproductive status. Analysis of other genetic biomarkers is needed to explain the high prevalence of breast cancer in young women to improve breast cancer management in Morocco.

**Introduction**

Worldwide, breast cancer (BC) is the first leading cancer in women with nearly half million deaths annually [1]. Breast cancer in young women is uncommon and very aggressive [2]. In the literature, there is not a wide definition of young women with breast cancer; sometimes they are defined as women under 35, sometimes women under 40 or 50 years [3–5]. In other publications, young women are attributed to all premenopausal women [6].

In developed countries, approximately 5–7% of breast cancer patients are diagnosed before 40 years [7], while in developing countries, the prevalence is much higher. In Morocco, the prevalence of Breast cancer in young women vary between 8% and 25.4%, which represent the highest levels published so far [3, 8, 9].

According to many authors, it has specific epidemiological, diagnostic and prognostic characteristics; up to consider youth as a pejorative prognostic factor [10]. In young patients, histological grade is usually high, the expression of hormone receptors is less important while overexpression of HER2 (Human epidermal growth factor receptor 2) is higher than in older patients. In this subgroup, the triple negative tumors are more common [2]. The occurrence of cancer in this age generates fertility and sexuality problems, mainly related to aggressive treatments [11].

The identification of risk factors related to this disease and the optimization of care pathways are essential to optimize the cancer management, to enhance the chance of complete healing and to improve the life quality of patients.

Therefore, this retrospective study was planned to characterize breast cancer in young women as compared to breast cancer in older women. Characterization of Breast cancer in young women will focus on the epidemiological, clinic-pathological, biomarker expression and treatment characteristics. The comparison will be also applied on the recurrence and survival to identify the prognostic factors. Additionally, other risk factors, including oral contraceptive use, family history of breast cancer and obesity, will be assessed for their association with the aggressive development of breast cancer in this subgroup.
Methods

Study design and population

Our study consists of all breast cancer in Moroccan women diagnosed and/or followed up at the National Institute of Oncology in Rabat, Morocco during 2009. A total of 905 patients were recorded. Men patients, cases with missed data and foreign patients (n = 189) were then excluded. The remaining 716 breast cancer cases were divided according to their age into two groups. Group 1 (G1), regrouping 178 patients aged 40 years or less, and Group 2 (G2) including 538 patients more than 40 years old. The median age of young women at diagnosis was 36.5 ± 4.11, for older women, it was 52 ± 9.6.

Data collection

Data were obtained from patients’ medical files. The medical records were retrospectively reviewed and collected using SPSS-software. For each case, we abstracted all information on age, parity, weight/height, and hormonal status, familial history of breast cancer, clinical data, cancer stage, tumor size, histological type, tumor grade, lymph node involvement, metastases, hormonal receptors, treatment (surgery, chemotherapy, radiation therapy, hormonal therapy) and follow-up.

Histological type was updated according to the WHO classification of breast tumors 2012 (World Health Organization) [12]. Tumor pTNM (pathological Tumor Node Metastasis) staging is consistent with the seventh edition of AJCC classification (American Joint Committee on Cancer) of 2009. Tumor grade was assessed according to Scarff-Bloom & Richardson (SBR) grading system modified by Ellis and Elston [13] and vascular invasion was quantified histologically.

Estrogen and Progesterone receptors (ER and PR) were considered positive when nuclear expression was observed in at least 10% of the tumor cells.

Immunohistochemical expression of Her 2 was defined according to cytoplasmic membrane staining of the infiltrative component taking into account the complete or incomplete membrane staining, the intensity and the % of cells stained. Results are expressed in scores: 0/1+: negative, 2+: ambiguous and 3+: positive. In cases of ambiguous, Fluorescent in situ hybridization (FISH) was performed to assess Her 2 amplification. If Her 2 amplification is confirmed by FISH, the result was considered as positive.

According to ER, PR and Her2 status, breast cancer cases were classified into five subgroups: Luminal A (ER+/PR+/Her2-), Luminal B Her2- (ER+/PR- or lower than 20% /Her2-), Luminal B Her+ (ER+/PR+ or—/Her2+), Her2 (ER-/PR-/Her2+) and triple negative (ER-/PR-/Her2-) [14].

Follow-up

Patients were followed up until December 2014. Event free survival (EFS) was calculated from the date of surgery or the date of starting chemotherapy to the date of loco-regional recurrence or distant metastasis.

Statistical analysis

Statistical analysis was assessed by SPSS 13.0 software (IBM). Descriptive variables were expressed as means ± SD or medians (interquartile range). The χ2 test was used to analyze differences between qualitative data. Calculation of survival rates was performed by the Kaplan-Meier method and compared using the Log-rank test.
Univariate and multivariate Cox's regression model was performed to compare variables and outcome. A value of \( p < 0.05 \) is considered significant. In the multivariate model, all parameters reported in previous studies as influencing survival rates were included. These parameters were not necessarily significant in the univariate model.

**Ethics approval**

The study was approved by the Ethical Committee of Biological Research, Faculty of Medicine and Pharmacy–Rabat, and was conducted with respect to legal aspects. No consent was needed for this retrospective study and data were re-identified.

**Results**

**Clinicopathological characteristics**

Clinical and pathological data are reported respectively in Tables 1 and 2. Overall, breast cancer in Morocco is characterized by a median age at diagnosis of 48.9 ± 11.6, with extreme ages at 21 and 89 years. BC cases are mainly sporadic and only 14.5% of cases have a familial history of BC, with low level of metastatic evolution (only 18.2%) and presents a predominance of median stages (69.6% of cases have BC with stages II and III). In young women, clinical data report the same distribution as reported for breast cancer cases. Comparison between young and older women showed a statistically significant difference for metastatic progression \((p = 0.03)\). Indeed, 26.9% of young patients exhibited metastatic/relapse progression compared to 17.3% of women over 40 years old. For the other parameters, no statistically significant difference was observed. Interestingly, only 10.02% of young women with BC are obese, whereas in older women 33.6% of cases are obese.

Pathological data showed that BC is mainly ER+ (68.1%), PR+ (71.9%) and HER2- (77%). In our cohort, 16.8% of cases are triple negative, 40% have lymph node N0. Histological data showed that invasive carcinoma and the SBR grade II prevail. In young women, pathological data report the same distribution as reported for breast cancer cases. Comparison between young and older women showed a statistically significant difference for progesterone receptor expression (PgR). In fact, 79.9% of young women with BC are PgR+, whereas PgR positivity was reported only in 69.1% of older women with BC \((p = 0.01)\). For the other parameters, no statistically significant difference was observed. Of particular interest, 38.6% of young patients and only 29% of older women have SBR grade III. Even statistical analysis showed that there is no difference, a tendency to high SBR grade is observed for young women.

**Treatment**

Overall, young and older women received the same treatments. Neoadjuvant chemotherapy was given to 26 young women (18.3%) and to 76 older women (18.1%) \((p = 0.90)\). Radical mastectomy along was undergone to 74.9% of older women and to 70.8% of young women \((p = 0.30)\). Adjuvant chemotherapy was administered to 73.5% of young women and to 69.1% of older women \((p = 0.30)\).

Herceptin treatment, reserved to patients Her2 positives, was given to 11.6% of young patients (19/164) and to 7.3% of older women (34/468). Statistical analysis showed that there is no significant difference using this targeted therapy between young and older women \((p = 0.08)\).

Hormonal therapy was provided to patients with positive hormone receptors. Overall, 53.7% of young patients (88/164) and 48.6% of older patients (228/469) have received
hormonal therapy, with no significant difference ($p = 0.26$). Finally, radiotherapy was performed on nearly 57% of patients from each group with no statistical difference ($p = 0.90$).

Data analysis of metastatic patients

Among the 716 subjects of our database, 117 (16.34%) patients were metastatic at diagnosis. Among them, 23 are young women and 94 are older women, representing respectively 13.8% and 19.7% of all young and older women with breast cancer. Table 3 illustrates the comparison of some relevant parameters in the two groups of patients with metastatic disease.

Overall, no statistical difference was observed between young and older patients regarding the nulliparity at breast cancer diagnosis, ER status and metastasis localization. However, older women have the tendency to develop metastasis in bone (44.7%), whereas young patients develop metastasis in many organs, including bone (26.1%) and liver (26.1%).

Oral contraception use and progesterone receptor expression were statistically significant with $p$-values of 0.03 for the two parameters. In fact, 95% of young women (19/20) and only 74% of older women (54/73) have a high expression of PgR. Among young women, 53.3% use oral contraception (8/15) whereas only 24% of older women (12/50) had used it. Interestingly, no young woman is obese and 35.5% of older women (22/62) are obese.

Event Free Survival (EFS) analysis

The estimated median follow-up period was 31 months [11–53] with a range of 3 to 87 months. During the follow-up period, 29 young patients (26.9%) and 50 older patients (17.3%) had recurrence ($p = 0.03$).
Event free survival (EFS) was calculated using univariate analysis by Kaplan-Meier method. The results are reported in Fig 1. The 3-years EFS of patients with local disease were 74.6% and 85.1% for young and older women, respectively. The 5-years EFS was also higher in older patients (71.5%) than in young patients (64.6%) and this difference is statistically significant ($p = 0.04$).

Results of EFS correlation to some relevant parameters are represented in Fig 2. EFS is poorer in young women with negative estrogen receptors ($p = 0.02$). In aged women, EFS is better in patients with negative lymphnodes ($p = 0.00$).

### Univariate and Multivariate Cox regression analysis

The results of univariate and multivariate Cox regression analysis are reported in Table 4. Univariate analysis indicated that T3 tumors size, ER negative, absence of chemotherapy and absence of hormonal therapy are statistically the significant parameters influencing event free survival in young women. The multivariate analysis in the same group showed that the absence of hormonal therapy along with negative PgR status, T3 tumors size and nulliparity are associated with poorer EFS.
In the older group, univariate analysis showed that inflammatory breast cancer, T2 tumors, N+ status, absence of radiotherapy, absence of chemotherapy and absence of hormone therapy are associated with poorer EFS. The same results were found with the multivariate analysis except for T2 tumors, which were not associated with poorer EFS.

In the older group, univariate analysis showed that inflammatory breast cancer, T2 tumors, N+ status, absence of radiotherapy, absence of chemotherapy and absence of hormone therapy are associated with poorer EFS. The same results were found with the multivariate analysis except for T2 tumors, which were not associated with poorer EFS.
Discussion

The prevalence of breast cancer in young women is low but the impact of the disease is significant. In this study, young women under 40 years represent 24.9% of all women with breast cancer. Previous studies in Morocco reported disparate results, ranging from 8 to 25.4 [3, 8, 9, 15]. Worldwide, the prevalence of breast cancer in young women is variable. In USA, breast cancer in young women is lower, only 6.4% of patients with breast cancer are under 40 years [4]. The same data was reported in Italy [16]. However, recent study conducted in Switzerland, patients
Table 4. Univariate and multivariate Cox regression analysis for Event free survival (EFS).

| Parameters                      | women ≤ 40y | women > 40y |
|---------------------------------|-------------|-------------|
|                                 | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|                                 | HR 95% CI p   | HR 95% CI p   | HR 95% CI p   | HR 95% CI p   |
| Nulliparity                     | No           | Yes         | No           | Yes          |
|                                 | 1            | 1.41 0.66–3.02 0.37 | 1.20 1.16–4.45 0.003 | 0.57 0.24–1.35 0.200 |
| Oral contraceptives use         | No           | Yes         | No           | Yes          |
|                                 | 1            | 0.74 0.32–1.70 0.48 | 0.57 0.25–1.28 0.170 |
| Familial history of Breast cancer | No          | Yes         | No           | Yes          |
|                                 | 1            | 1.25 0.42–3.67 0.68 | 0.57 0.20–1.60 0.280 |
| Obesity                         | No           | Yes         | No           | Yes          |
|                                 | 1            | 1.11 0.32–3.81 0.86 | 1.15 0.58–2.30 0.670 |
| Inflammatory breast cancer      | No           | Yes         | No           | Yes          |
|                                 | 1            | 0.64 0.35–1.18 0.15 | 1.66 1.45–1.96 0.003 | 0.64 0.00–0.34 0.001 |
| Tumor size                      | ≤20mm        | No          | Yes          | Yes          |
|                                 | 1            | 1.08 0.27–2.91 0.84 | 1.35 0.25–7.29 0.72 | 2.69 1.00–5.32 0.049 |
|                                 | 21–50 mm     | 0.84 0.84–4.37 0.33 | 1.35 0.25–7.29 0.72 | 2.69 1.00–5.32 0.049 |
|                                 | >50mm        | 4.94 1.29–18.9 0.01 | 17.39 1.74–173.34 0.01 | 0.58 0.25–5.70 0.31 |
| SBR grade:                      | SBR I        | Yes         | Yes          | Yes          |
|                                 | 1            | 0.79 0.27–2.92 0.67 | 1.19 0.27–5.09 0.810 |
|                                 | SBR II       | 1.15 0.39–3.42 0.79 | 1.99 0.45–8.63 0.350 |
|                                 | SBR III      | 1.15 0.39–3.42 0.79 | 1.99 0.45–8.63 0.350 |
| N status                        | N-           | No          | Yes          | Yes          |
|                                 | 1            | 1.1 0.49–2.42 0.81 | 3.44 0.55–21.45 0.18 | 2.48 1.21–5.06 0.001 |
|                                 | N+           | 1.1 0.49–2.42 0.81 | 3.44 0.55–21.45 0.18 | 2.48 1.21–5.06 0.001 |
| Stage                           | I            | Yes         | Yes          | Yes          |
|                                 | 1            | 1.08 0.27–2.91 0.84 | 1.35 0.25–7.29 0.72 | 2.69 1.00–5.32 0.049 |
|                                 | II           | 2.77 0.35–21.7 0.33 | 1.35 0.25–7.29 0.72 | 2.69 1.00–5.32 0.049 |
|                                 | III          | 3.84 0.49–30.1 0.20 | 1.35 0.25–7.29 0.72 | 2.69 1.00–5.32 0.049 |
| ER                              | positive     | No          | Yes          | Yes          |
|                                 | 1            | 0.38 0.18–0.83 0.01 | 0.41 0.06–2.54 0.34 | 0.39 0.06–2.54 0.34 |
|                                 | negative     | Yes         | Yes          | Yes          |
|                                 | 1.00 1.00–1.00 1.00 | 0.84 0.39–2.05 0.84 | 0.41 0.06–2.54 0.34 | 0.39 0.06–2.54 0.34 |
| PgR                             | positive     | Yes         | Yes          | Yes          |
|                                 | 1            | 0.59 0.26–1.36 0.21 | 19.85 1.07–366.54 0.04 | 0.86 0.47–1.59 0.64 |
|                                 | negative     | Yes         | Yes          | Yes          |
|                                 | 0.73 0.27–1.96 0.54 | 6.79 0.62–73.99 0.11 | 1.48 0.7–3.13 0.29 | 1.99 0.47–8.43 0.34 |
| HER2                            | positive     | No          | Yes          | Yes          |
|                                 | 1            | 0.73 0.27–1.96 0.54 | 6.79 0.62–73.99 0.11 | 1.48 0.7–3.13 0.29 |
|                                 | negative     | No          | Yes          | Yes          |
|                                 | 1.00 1.00–1.00 1.00 | 0.59 0.26–1.36 0.21 | 19.85 1.07–366.54 0.04 | 0.86 0.47–1.59 0.64 |
| Molecular subtype               | Luminal A    | No          | Yes          | Yes          |
|                                 | 1            | 3.20 0.9–11.42 0.07 | 0.54 0.12–2.31 0.400 |
|                                 | Luminal B HER2- | 0.85 0.24–3.05 0.81 | 1.26 0.50–3.12 0.610 |
|                                 | Luminal B HER2+ | 1.29 0.29–5.80 0.73 | 2.23 0.66–7.52 0.190 |
|                                 | HER2         | 1.29 0.29–5.80 0.73 | 2.23 0.66–7.52 0.190 |
|                                 | Triple negative | 1.74 0.61–4.95 0.29 | 1.29 0.55–3.05 0.550 |
|                                 | 1.74 0.61–4.95 0.29 | 1.29 0.55–3.05 0.550 |
| Surgery type                    | Radical mastectomy | 1.00 1.00–1.00 1.00 | 0.54 0.20–1.44 0.22 | 3.75 0.61–22.87 0.15 |
|                                 | Conserving surgery | No          | Yes          | Yes          |
|                                 | 1            | 0.51 0.23–1.10 0.08 | 1.15 0.11–11.16 0.90 | 0.36 0.15–1.58 0.460 |
|                                 | No           | Yes          | Yes          | Yes          |
|                                 | 1.00 1.00–1.00 1.00 | 0.51 0.23–1.10 0.08 | 1.15 0.11–11.16 0.90 | 0.36 0.15–1.58 0.460 |
| Chemotherapy                    | No           | Yes          | Yes          | Yes          |
|                                 | 1.00 1.00–1.00 1.00 | 0.45 0.19–1.00 0.0049 | 1.15 0.11–11.16 0.90 | 0.36 0.15–1.58 0.460 |
|                                 | Trastuzumab   | No           | Yes          | Yes          |
|                                 | 1.00 1.00–1.00 1.00 | 0.42 0.10–1.78 0.24 | 0.11 0.00–4.15 0.23 | 0.86 0.31–2.41 0.78 |
|                                 | Hormone therapy | No          | Yes          | Yes          |
|                                 | 1.00 1.00–1.00 1.00 | 0.41 0.19–0.86 0.01 | 0.11 0.00–0.75 0.03 | 0.35 0.20–0.61 0.003 |

HR: hazard Ratio; CI: confidence interval; SBR: Scarff-Bloom Richardson classification; N: Node.

doi:10.1371/journal.pone.0164841.t004

Aged between 20 and 39 years represented 23.4% of all breast cancer cases which concords with our findings [17]. In Algeria, young women represent 12% of breast cancer cases [18]. Breast cancer is a complex and heterogeneous disease associated with clinical, pathological and biological factors largely variable from a population to another. To our knowledge, the
current analysis represents the first large comparative study of risk factors as outcome predictors in young versus older breast cancer patients in Morocco. It was conducted in the National Institute of Oncology in Rabat, considered as a reference public health oncology center.

In this study, nulliparity at diagnosis is more frequent in young women with breast cancer than in older women with a significant difference. Our results agree with already reported studies. Indeed, previous studies have focused their interest on the nulliparity status as a risk factor for breast cancer development. MacMahon have reported that nulliparous women have a higher risk of breast cancer than parous women [19]. In a Japanese study, Tamakoshi et al. have clearly showed that reproductive factors, particularly the number of parity and age at first delivery, might be important in the etiology of breast cancer among Japanese women [20]. The increased risk of breast cancer in nulliparous women could be attributed to the high levels of prolactin and circulating oestradiol than in parous and/or older women [21]. Moreover, high parity increases the initiation of tumor cells during breast tissue maturation that occurs repeatedly with every pregnancy [22], explaining the overall high frequency of multiparity in young and older breast cancer women.

Currently, it is widely accepted that obesity increases BC risk in postmenopausal women and is associated with reduced risk of BC for premenopausal women [23]. In our study, only 10.2% of young women and 33.6% of older women with breast cancer were obese. In premenopausal women, obesity is associated with absence of ovulation and lower levels of circulating estrogen levels that decrease the risk of developing breast cancer [23].

Tumors in the young group are more aggressive with high SBR grades, lymph node involvement and high tumor size, but still not significant when compared with the older group. Several studies indicate that tumors in young women are more advanced and explained it by the delay of diagnosis and the lack of awareness [3, 8, 24].

The difference in hormone receptors expression was also investigated and a statistically significant difference was observed for PgR. PgR positivity is usually correlated to a better prognosis and less recurrence [25]. In this study, the expression of PgR in young women was more frequent than in older women with breast cancer ($p = 0.01$). Our results are in agreement with previous reported data showing that postmenopausal women have low PgR expression than premenopausal women [26].

ER status did not show a significant difference between young and older women with breast cancer, while many studies have demonstrated more negativity in hormonal receptors in young women [4, 27]. Of particular interest, ER status is influenced by the patient’s obesity. In fact, obese postmenopausal women are more likely to be ER+ than obese premenopausal women, because adipose tissue is the primary source of estrogen production via aromatase enzyme conversion of androgenic precursors increasing the risk of breast cancer [23, 25].

Currently, a great interest was given to molecular subtypes as factors influencing breast cancer outcome. Accordingly, TNBC are more aggressive and show low clinical and pathological response to chemotherapy compared to the remaining subtypes, especially Luminal A [28]. Many authors showed that TNBC is more frequent in young women [29, 30]. In our study, TNBC was reported in both young and older women with no statistical difference. Moreover, TNBC was associated with poorer EFS, which is in agreement with previously results [28, 29, 31]. Hormonal treatment is always correlated to better outcome hence the interest of this therapy[3]. The non-administration of hormonal therapy to TNBC subtypes, due to their hormones receptors status, may explain the great association between TNBC and poorer EFS. Therefore, and in the absence of genetic profiling, molecular subtypes are still a good prognostic factor of response to adjuvant treatments and survival prediction.

Relapse was more frequent in young women as compared to older women with breast cancer ($p = 0.03$). This difference could be explained by the tumor aggressiveness in this subgroup.
as reported in many studies [2, 10, 32]. In fact, SBR III grade and high tumor size prevail in young women than older women.

Kaplan-Meier analysis clearly showed that EFS in young women was poorer than in older women, which is in agreement with already published results in Morocco and other countries [3, 8, 33]. It is widely accepted that survival rate can be influenced by several parameters including oral contraception use and nulliparity. In this study, results highlighted that EFS is poorer among oral contraceptive users. Recent studies found an increased risk of breast cancer among OC users [34, 35], but this correlation is still controversial and subject to several ongoing studies.

EFS was also influenced by the nulliparity status at breast cancer diagnosis, which is in agreement with previously reported data showing an association between poor survival with nulliparity that could be explained by the absence of breast tissue maturation that occurs during pregnancy and breastfeeding [22]. Moreover, Gleicher had hypothesized that the remaining stem cells in reproductive organs might be de-inhibited and lead to cancer development at advanced ages [36]. Further investigations are needed to better understand this relevant association.

In our cohort, treatment did not show significant difference, however we noted a higher proportion of treated young patients suggesting that young patients are more aggressively treated than older patients are. As already reported, tumors in young women were more aggressive. These finding are in total agreement with results obtained by El Saghir et al. [37].

In this study, 12.9% of young women and 17.47% of older women have developed metastasis. In the young group, metastasis appears to be correlated with positive progesterone expression and oral contraceptive use ($p = 0.03$). It is widely accepted that oral contraceptives are high risk factor of breast cancer. Moreover, the delay of diagnosis registered in the young group, may also explain the rapid progression of the disease [34, 35].

The main limitation of the study is the absence of date of death in the medical records, which limited the calculation of overall survival. Moreover, the lack of information regarding some parameters could have influenced their investigation.

Conclusions

In Morocco, breast cancer is more frequent in young women as compared to western countries. Breast cancer in young women is more aggressive and is diagnosed late, leading to an intensive treatment. We can also assume that the main factors associated with breast cancer development in young women are hormonal and reproductive status. Larger multi-institutional studies, including evaluation of genetic biomarkers, are needed to confirm our results and explain the high prevalence of breast cancer in young women to improve breast cancer management in Morocco.

Acknowledgments

We thank Dr Erraki Mohamed from the epidemiology unit at the National Institute of Oncology and his team for providing us necessary medical records needed for the study.

Author Contributions

Conceptualization: MS MEM MA.

Data curation: MS FZM IG RZ MEM MA.

Formal analysis: MS IG RZ.
Investigation: MS MEM.
Methodology: MS MEM MA.
Project administration: MS MA.
Resources: MS FZM MEM MA.
Software: MS IG RZ.
Supervision: MA.
Validation: MS MEM.
Visualization: MS FZM IG RZ MEM MA.
Writing – original draft: MS.
Writing – review & editing: MS FZM IG RZ MEM MA.

References
1. GLOBOCAN. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. 2012.
2. Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhiedine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. Journal of thoracic disease. 2013; 5(Suppl 1):S2. doi: 10.3978/j.issn.2072-1439.2013.05.24 PMID: 23819024
3. Abahssain H, Lalya I, El M'rabet F Z, Ismailli R, Razine R, Tazi MA, et al. Breast cancer in moroccan young women: a retrospective study. BMC research notes. 2010; 3:286. doi: 10.1186/1756-0500-3-286 PMID: 21059204; PubMed Central PMCID: PMC2992542.
4. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. Journal of the American College of Surgeons. 2009; 208(3):341–7. doi: 10.1016/j.jamcollsurg.2008.12.001 PMID: 19317994; PubMed Central PMCID: PMC3262236.
5. Black WC, Nease RF, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. Journal of the National Cancer Institute. 1995; 87(10):720–31. PMID: 7563149
6. Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes & Control. 2003; 14(2):151–60.
7. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009; 4(11):e7695. doi: 10.1371/journal.pone.0007695 PMID: 19907647; PubMed Central PMCID: PMC2770847.
8. Boufettal H, Noun M, Samouh N. Breast cancer in young patient in Morocco. Cancer radiotherapie: journal de la Societe francaise de radiotherapie oncologique. 2010; 14(8):698–703. doi: 10.1016/j.canrad.2010.04.007 PMID: 20674443.
9. Znati K, Bennis S, Abbass F, Akasbi Y, Chbani L, Elfatemii H, et al. Breast cancer in young patient in Morocco. Gynecologie, obstetrique & fertilite. 2014; 42(3):149–54. doi: 10.1016/j.jyobfe.2011.08.014 PMID: 22521987.
10. Jr HAA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014; 16:427. doi: 10.1186/s13058-014-0427-5 PMID: 25436920
11. Reyna C, Lee MC. Breast cancer in young women: special considerations in multidisciplinary care. Journal of multidisciplinary healthcare. 2014; 7:419–29. doi: 10.2147/JMDH.S49994 PMID: 25300196; PubMed Central PMCID: PMC4189712.
12. Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care (Basel). 2013; 8(2):149–54. doi: 10.1159/000350774 PMID: 24413964; PubMed Central PMCID: PMC3683948.
13. Singley SE, Alred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. Journal of clinical oncology. 2002; 20(17):3628–36. PMID: 12202863
14. Goldhirsh A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert
Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology. 2013; 24(9):2206–23. doi: 10.1093/annonc/mdt303 PMID: 23917950

15. Abbass F, Bennis S, Znati K, Akasbi Y, Amrani J, El Mesbahi O, et al. Le profil épidémiologique et biologique du cancer du sein à Fès-Boulemane (Maroc). EMHU. 2011; 17(12).

16. Ghilli M, Lo Russo M, Colizzi L, Rossetti E, Camilleri V, Roncella M. Breast cancer in young patients: report of the activity of 12 months in a dedicated breast cancer center in Italy. Biological, treatment-related and organizational peculiar aspects. The Breast. 2014; 23S1:S12–S23.

17. Bodmer A, Feller A, Bordoni A, Bouchardy C, Dehler S, Ess S, et al. Breast cancer in younger women in Switzerland 1996–2009: a longitudinal population-based study. Breast. 2015; 24(2):112–7. doi: 10.1016/j.breast.2014.11.004 PMID: 25522906.

18. Guendouz H, Abdelouahab A, Bendib A. Cancer du sein de la femme de moins de 35 ans: étude rétrospective à propos de 612 cas. Société Française de Sénologie et de Pathologie mammaire. 2010. doi: 10.1111/j.1349-7006.2004.00010.x

19. MacMahon B. Reproduction and cancer of the breast. Cancer. 1993; 71(10):3185–8. PMID: 8490850

20. Tamakoshi K, Yatsuya H, Wakai K, Suzuki S, Nishio K, Lin Y, et al. Impact of menstrual and reproductive factors on breast cancer risk in Japan: Results of the JACC study. Cancer Science. 2005; 96(1):57–62. doi: 10.1111/j.1349-7006.2005.00010.x PMID: 15649257.

21. Parsa P, Parsa B. Effects of Reproductive Factors on Risk of Breast Cancer: A. Asian Pacific Journal of Cancer Prevention. 2009; 10:545–50. PMID: 19827866

22. Butt S, Borgquist S, Game JP, Landberg G, Tengrup I, Olsson A, et al. Parity in relation to survival following breast cancer. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2009; 35(7):702–8. doi: 10.1016/j.ejso.2008.03.017 PMID: 18490128.

23. Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiologic reviews. 2014; 36:114–36. doi: 10.1093/epirev/mxt010 PMID: 24375928; PubMed Central PMCID: PMC3873844.

24. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007; 9(1):R6. doi: 10.1186/bcr1639 PMID: 17239243

25. Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, et al. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Clinical breast cancer. 2015; 15(3):204–11. doi: 10.1016/j.clbc.2014.12.007 PMID: 25600243.

26. Bharat A, Aft RL, Gao F, Margenthaler JA. Patient and tumor characteristics associated with increased mortality in young women (≤40 years) with breast cancer. Journal of surgical oncology. 2009; 100(3):248–51. doi: 10.1002/jso.21268 PMID: 1930819

27. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical medicine & research. 2009; 7(1–2):4–13.

28. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007; 109(9):1721–8. doi: 10.1002/cncr.22618 PMID: 17387718

29. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Critical reviews in oncology/hematology. 2010; 76(1):44–52. doi: 10.1016/j.critrevonc.2009.09.002 PMID: 19808012.

30. Keegan TH, Press DJ, Tao L, DeRouen MC, Kurian AW, Clarke CA, et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res. 2013; 15(5):R95. doi: 10.1186/bcr3556 PMID: 24131591; PubMed Central PMCID: PMC3978627.

31. Gabriel CA, Domchek SM. Breast cancer in young women. Breast Cancer Res. 2010; 12(5):212. doi: 10.1186/bcr2647 PMID: 21067532

32. Han W, Kim S, Park IA, Kang D, Kim S-W, Youn Y-K, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC cancer. 2004; 4(1):1.
34. Bethea TN, Rosenberg L, Hong C- C, Troester MA, Lunetta KL, Bandera EV, et al. A case–control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium. Breast cancer research: BCR. 2015; 17(1):535–.

35. Beaber EF, Malone KE, Tang M- TC, Barlow WE, Porter PL, Daling JR, et al. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiology Biomarkers & Prevention. 2014; 23(5):755–64.

36. Gleicher N. Why are reproductive cancers more common in nulliparous women? Reproductive Biology Medicine Online. 2013; 26(5):416–9. doi: 10.1016/j.rbmo.2013.01.007 PMID: 23518034

37. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, et al. Effects of young age at presentation on survival in breast cancer. BMC cancer. 2006; 6(1):194.